|
EP2433650A2
|
|
Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
|
|
CN101218257A
|
|
GITR binding molecules and uses therefor
|
|
EP1758936A2
|
|
Optimized dosing with anti-cd4 antibodies for tolerance induction in primates
|
|
US2005048587A1
|
|
Methods for identifying tolerance modulatory compounds and uses therefor
|
|
WO2004052398A1
|
|
Inducing tolerance in primates
|
|
US2004166099A1
|
|
Molecules preferentially associated with effector T cells and methods of their use
|
|
WO2004032867A2
|
|
Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use
|
|
US7541443B2
|
|
Anti-CD4 antibodies
|
|
EP1985306A2
|
|
CD4-specific antibody TRX1 and uses therefor
|
